Gene Silencing Hormones Life Science Production 
pharmaphorum
JUNE 8, 2022
The passport means that LentiGlobin will be reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new innovative licensing and access pathway (ILAP) introduced in 2020, which reduces the review time for a new medicine to 150 days.
pharmaphorum
DECEMBER 23, 2020
It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. Biogen and Denali will co-market the lead LRRK2 product in the US and China, and Biogen will commercialise in all other markets. Rare disease progress.
Expert insights. Personalized for you.
52 
Let's personalize your content